China's first domestically developed nine-valent HPV vaccine officially received market approval this month after 18 years of research by Xiamen University and Wantai BioPharm.

The newly-approved vaccine is the world's second nine-valent cervical cancer vaccine, reinforcing China's capacity for vaccine innovation.